
    
      The present study is a randomized, double-blind, placebo-controlled, parallel, phase II
      clinical trial that will assess the efficacy and safety of transcutaneous magnetic spinal
      cord stimulation in PD patients who have gait and balance changes refractory to dopaminergic
      therapy.
    
  